关节与肌肉骨骼软组织皮质类固醇注射的使用与安全:多学会指南
该指南由美国区域麻醉与疼痛医学学会等四家学会制定,聚焦成人关节慢性疼痛的皮质类固醇注射安全性与有效性。指南采用改良Delphi法和USPSTF证据分级,经四轮讨论形成推荐,涉及肩、肘、手、腕、髋、膝及手足小关节。
要点
- 超声引导可提高关节注射准确性并减轻操作疼痛。
- 肩关节和肩峰下-三角肌下滑囊注射中,曲安奈德20mg与40mg疗效相当。
- 膝关节注射中,曲安奈德40mg与80mg疗效相当。
核心结论
- 关节内皮质类固醇注射可提供数周至数月的短期疼痛缓解。
- 不良事件包括血糖升高、肾上腺抑制、对关节软骨的不利影响、骨密度降低及术后关节感染。
研究设计与样本
- 指南制定经美国区域麻醉与疼痛医学学会董事会及参与学会批准,由皮质类固醇安全工作组协调。
- 采用改良版USPSTF证据分级和推荐强度,并通过改良Delphi流程达成共识,经四轮讨论后所有声明和推荐获全体参与者及参与学会董事会批准。
主要发现
- 多数研究报道短期获益,长期缓解结果不一。
- 推荐的有效剂量低于临床医生目前使用的剂量。
- 很少有证据指导一种皮质类固醇优于另一种的选择。
- 超声引导提高注射准确性并减少操作疼痛。
关键数值与推荐
- 肩关节内注射和肩峰下-三角肌下滑囊注射:曲安奈德20mg与40mg疗效相当。
- 髋关节内注射常用剂量为曲安奈德40mg或甲泼尼龙40mg。
- 膝关节内注射:曲安奈德40mg与80mg疗效相当。
临床怎么用
- 成人关节慢性疼痛可考虑关节内皮质类固醇注射以获得短期疼痛缓解。
- 推荐使用超声引导以提高注射准确性并减轻操作疼痛。
- 肩关节注射可选用曲安奈德20mg,膝关节注射可选用曲安奈德40mg。
局限性
- 长期缓解的证据结果不一。
- 很少有证据指导皮质类固醇药物的选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intra-articular corticosteroid (IACS) injection and peri-articular corticosteroid injection are commonly used to treat musculoskeletal conditions. Results vary by musculoskeletal region, but most studies report short-term benefit with mixed results on long-term relief. Publications showed adverse events from single corticosteroid injections. Recommended effective doses were lower than those currently used by clinicians. METHODS: Development of the practice guideline for joint injections was approved by the Board of Directors of the American Society of Regional Anesthesia and Pain Medicine and the participating societies. A Corticosteroid Safety Work Group coordinated the development of three guidelines: peripheral nerve blocks and trigger points; joints; and neuraxial, facet, and sacroiliac joint injections. The topics included safety of the technique in relation to landmark-guided, ultrasound-guided, or radiology-aided injections; effect of the addition of the corticosteroid on the efficacy of the injectate; and adverse events related to the injection. Experts on the topics were assigned to extensively review the literature and initially develop consensus statements and recommendations. A modified version of the US Preventive Services Task Force grading of evidence and strength of recommendation was followed. A modified Delphi process was adhered to in arriving at a consensus. RESULTS: This guideline focuses on the safety and efficacy of corticosteroid joint injections for managing joint chronic pain in adults. The joints that were addressed included the shoulder, elbow, hand, wrist, hip, knee, and small joints of the hands and feet. All the statements and recommendations were approved by all participants and the Board of Directors of the participating societies after four rounds of discussion. There is little evidence to guide the selection of one corticosteroid over another. Ultrasound guidance increases the accuracy of injections and reduces procedural pain. A dose of 20 mg triamcinolone is as effective as 40 mg for both shoulder IACS and subacromial subdeltoid bursa corticosteroid injections. The commonly used dose for hip IACS is 40 mg triamcinolone or methylprednisolone. Triamcinolone 40 mg is as effective as 80 mg for knee IACS. Overall, IACS injections result in short-term pain relief from a few weeks to a few months. The adverse events include an increase in blood glucose, adrenal suppression, detrimental effect on cartilage lining the joint, reduction of bone mineral density, and postoperative joint infection. CONCLUSIONS: In this practice guideline, we provided specific recommendations on the role of corticosteroids in joint, bursa, and peritendon injections for musculoskeletal pain.
引用
- Benzon HT, Provenzano DA, Nagpal A, et al. Use and safety of corticosteroid injections in joints and musculoskeletal soft tissue: guidelines from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, the American Society of Interventional Pain Physicians, and the International Pain and Spine Intervention Society. Reg Anesth Pain Med. 2026. PMID: 40015722. doi:10.1136/rapm-2024-105656
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。